PvP Biologics is developing KumaMax, an oral enzyme designed to break down immuno-reactive components of gluten in the stomach, thereby preventing the gastrointestinal symptoms associated with celiac disease. This therapeutic approach aims to alleviate the burden of strict gluten-free diets for the estimated 2.4 million Americans affected by the condition.
Funding
Funding not disclosed
Founders
Product
Problem
Celiac disease, affecting an estimated 2.4 million Americans, is characterized by acute gastrointestinal symptoms, malnutrition, and increased mortality. The primary treatment is a strict gluten-free diet, which is costly, challenging to maintain, and often fails to eliminate persistent symptoms.
Solution
PvP Biologics is developing KumaMax, an oral enzyme therapeutic designed to address celiac disease by breaking down immuno-reactive components of gluten in the stomach. This approach aims to prevent the gastrointestinal symptoms and intestinal damage caused by accidental gluten ingestion, thereby reducing the burden associated with strict adherence to gluten-free diets. KumaMax, exclusively in-licensed by PvP Biologics, represents a novel strategy for managing celiac disease and improving the quality of life for affected individuals.
Target Audience
The primary target audience includes individuals diagnosed with celiac disease who experience persistent symptoms despite following a gluten-free diet, as well as those seeking a therapeutic alternative to manage accidental gluten ingestion.
Features
- Oral enzyme formulation designed to degrade gluten in the stomach
- Aims to prevent gastrointestinal symptoms and intestinal damage from gluten exposure
- Specifically targets immuno-reactive components of gluten
- Designed to reduce the burden of strict gluten-free diets